Acromegaly
Welcome,         Profile    Billing    Logout  
 22 Companies   9 Products   9 Products   6 Mechanisms of Action   44 Trials   4084 News 


«12...3536373839404142434445...6768»
  • ||||||||||  Journal:  A novel peptide antagonist of the human growth hormone receptor. (Pubmed Central) -  Aug 22, 2021   
    We observed a strong correlation between helical propensity and inhibitory effect, indicating that S1H-mediated antagonism of the hGHR is largely dependent on the ability for S1H to adopt an α-helix. Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions.
  • ||||||||||  Trial completion date, Trial primary completion date, Surgery:  Sleep Apnea in Acromegaly After Surgery (clinicaltrials.gov) -  Aug 20, 2021   
    P=N/A,  N=50, Recruiting, 
    Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions. Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal, HEOR:  Effects of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life in Acromegaly. (Pubmed Central) -  Aug 20, 2021   
    This large family adds new information on the p.R304Q AIP variant and data suggest two new candidate genes could be associated with growth hormone excess. Our data support a comparable QoL in patients receiving pegvisomant vs. somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs.
  • ||||||||||  Journal:  Looking above the heart: A rare cause of ventricular tachycardia. (Pubmed Central) -  Aug 14, 2021   
    The diagnosis was confirmed by elevated levels of insulin like growth factor-1 and the presence of a pituitary adenoma. Following trans-sphenoidal surgery, there was a reduction in PVC burden and no recurrence of VT.
  • ||||||||||  Journal:  Acromegaly and Vertebral Fractures: Facts and Questions. (Pubmed Central) -  Aug 14, 2021   
    Here I review vertebral fractures (VFs) as an emerging complication of acromegaly through a pathway of key questions in order to help clinicians manage the disease. Peculiarities of acromegalic osteopathy are that VFs are common but not explained by low bone mineral density (BMD) being related to disease duration and activity, and occurring even after remission.
  • ||||||||||  Retrospective data, Journal:  Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. (Pubmed Central) -  Aug 14, 2021   
    Klotho G395A polymorphism is associated with acromegaly susceptibility and increased risk of malignancy and colorectal polyps in these patients. There is only a minor sex differences in the epidemiology of acromegaly at the time of diagnosis except that female patients are slightly older and exhibit lower IGF-I concentrations and a longer diagnostic delay.
  • ||||||||||  Journal:  New developments and perspectives in acromegaly (Pubmed Central) -  Aug 12, 2021   
    The pharmaceutical arsenal now includes the first orally available somatostatin analogue, and recent data on possible drug combinations and the outcome of radiotherapy are presented. Finally, special attention is paid to older and pregnant patients, as well as certain considerations during the COVID-19 pandemic (where appropriate diagnosis and management of acromegaly is particularly challenging).
  • ||||||||||  temozolomide / Generic mfg.
    Review, Journal:  Multimodal therapy in aggressive pituitary tumors. (Pubmed Central) -  Aug 11, 2021   
    Multimodal therapy, implemented by experts, preferably in specialized centers with high volume caseload, is the only way to improve the prognosis of patients with these uncommon tumors. The research needs in this area are multiple and include a greater knowledge of the molecular biology of these tumors, establishment of protocols for monitoring and sequencing of treatments, development of multicenter studies and international registries.
  • ||||||||||  Journal:  Potential markers of disease behavior in acromegaly and gigantism. (Pubmed Central) -  Aug 11, 2021   
    Novel markers not included or only partially covered in previously published reviews on the subject were prioritized.Expert opinion: Recognizing the most relevant markers of disease behavior may help the medical team tailoring the strategies for approaching each case of acromegaly and gigantism. This customized plan should make the evaluation, treatment and follow up process more efficient, greatly improving the patients' outcomes.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    [VIRTUAL] Effect of GH / IGF1 System on Lung Cancer Cells A549 (ePoster Hall) -  Aug 9, 2021 - Abstract #IASLCWCLC2021IASLC_WCLC_1147;    
    Pegvisomant (PEG), an antagonist of GH receptor, was initially developed to treat patients with acromegaly, but it has shown potential to treat some tumors...Conclusion In conclusion, IGF1 antagonism is leading modulator in A549 lung cancer cells and autocrine/paracrine signaling in the GH/IGF1 axis is evidenced for adenocarcinoma cells, with changes in expression of GH and GH-receptor, which may imply that therapeutics need to be based on time changing kinase inhibitors and possible biomarkers to proper adjustments. Acknowledgements: the authors thank to I. Mendieta, J.E. Soto, J. Escobar, A.L. Gutiérrez for design and technical assistance; This work has been funded by Consejo Nacional de Ciencia y Tecnología (CONACYT) and UAQ-FCQ201820
  • ||||||||||  Clinical, Journal:  Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence? (Pubmed Central) -  Aug 3, 2021   
    Patients with acromegaly should be the focus of specially designed national programs, initiatives and/or guidelines for regular evaluation and improvement of the adherence level. Despite the difficulties and the lack of an adequate legal basis, successive steps initiated by different stakeholder are needed.
  • ||||||||||  Journal:  Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma. (Pubmed Central) -  Aug 1, 2021   
    GH secretion in a somatotroph cell line is partially dependent on KCNAB2 gene expression and may be mitigated in vitro by quinidine. These results collectively suggest a potential new target and pharmacological candidate to be considered in the development of clinical therapeutics for acromegaly.
  • ||||||||||  Clinical, Journal:  Plurihormonal pituitary macroadenoma:  a case report. (Pubmed Central) -  Jul 30, 2021   
    Our case further proves that immunohistochemical analyses of all pituitary hormones are needed to ensure correct diagnosis and to alert clinicians to the need for more rigorous follow-up due to the higher morbidity of these patients. Our case report approval number Federal Wide Assurance NIH, USA is FWA00018774 IRB registration number with OHRP/NIH is IRB00010471.
  • ||||||||||  Review, Journal:  An Opera Singer's Voice Mutation over Time Due to Acromegaly. (Pubmed Central) -  Jul 30, 2021   
    The authors present a very rare case of an opera singer with undetected acromegaly for years, whose tessiture progressively changed from tenor, to baritone, to bass. We analyze the evolution of vocal parameters over the years and the outcome after surgical treatment.
  • ||||||||||  Journal:  Hypothalamic hormone-producing tumors. (Pubmed Central) -  Jul 30, 2021   
    Biomarkers are used to classify these tumors and achieve accurate structure-function correlations. While surgery remains the mainstay of therapy, novel medical and radiopharmaceutical approaches are available for patients with progressive and/or unresectable tumors.
  • ||||||||||  Clinical, Review, Journal:  Endocrine causes of heart failure: A clinical primer for cardiologists. (Pubmed Central) -  Jul 29, 2021   
    Isolated presentation as pulmonary hypertension and right heart failure are also documented. Good history-taking and physical examination with targeted investigations will help in the timely management for reversing the pathophysiology to a significant extent by appropriated management.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Clinical, Journal:  Cognitive Functioning and Cortical Brain Thickness in Acromegaly Patients: A Pilot study. (Pubmed Central) -  Jul 24, 2021   
    In conclusion, in this pilot study, the type of pharmacological treatment in patients with acromegaly and good glycemic control did not influence the cognitive function and cortical brain thickness. However, pegvisomant could play a neuroprotective role on the thalamus that will have to be demonstrated with larger samples in future studies.
  • ||||||||||  Clinical, Journal:  Evaluation of Acromegaly patients with sleep disturbance related symptoms. (Pubmed Central) -  Jul 23, 2021   
    The probability of OSA occurrence and polysomnographic features between the genders are similar. Although the median BMI of the patients with and without OSA was similar, the median age was higher in the group with OSA, middle-aged acromegaly patients should be evaluated in terms of OSA even if there is no obvious obesity.
  • ||||||||||  Clinical, Clinical guideline, Journal:  The necessity and importance of standardized management of acromegaly: from the perspective of development of expert consensuses and clinical guidelines (Pubmed Central) -  Jul 20, 2021   
    Acromegaly is a rare disease, and multidisciplinary collaboration is essential for its diagnosis, treatment, and follow-up.In recent years, a series of novel findings have been echieved in clinical studies on acromegaly.Therefore, the China Pituitary Adenoma Specialist council has convened Chinese specialists in neurosurgery, endocrinology, radiology, and radiotherapy to release the Chinese Consensus for the Diagnosis and Treatment of Acromegaly (2021), which aims to promote the standardized and individualized management of acromegaly.Looking back to the past, the consensuses and guidelines have played vital roles in establishing the widely recognized biochemical remission criteria, promoting new drugs and novel therapeutic strategies which are of significance for standardized treatment, and emphasizing the need to focus on the systemic complications of acromegaly and the long-term quality of life. In this editorial, we briefly reviewed the expert consensuses and clinical guidelines on acromegaly at home and abroad, and discussed their important roles in promoting standardized disease management from three aspects including biochemical remission standards, medical treatment, and the diagnosis and treatment of systemic complications.
  • ||||||||||  Retrospective data, Journal:  Updated key points of Chinese Consensus for the Diagnosis and Treatment of Acromegaly (2021 edition) (Pubmed Central) -  Jul 20, 2021   
    Meanwhile, the diagnosis and treatment of acromegaly patients concurrent with other particular scenarios, including pregnancy and refractory pituitary GH-secreting adenoma is suggested. This article aims to describe the updated key points of the new version of the consensus, and thus facilitate the clinical implementation of standardized diagnosis and treatment for acromegaly patients.